Medartis H1 2026 slides: organic growth hits 17%, guidance raised
Medartis Group reported strong first-half 2026 results on August 18, 2026, in Basel, Switzerland, with a 30.7% year-over-year revenue increase to CHF 160.8 million. Organically, the company grew by 17.0% at constant exchange rates, and core EBITDA margin improved to 18.0%. CEO Matthias Schupp and CFO Peter Hackel presented the results, highlighting the company's execution on strategic priorities.
Management raised full-year guidance for organic growth and profitability. The strong performance was driven by the international expansion of the TOUCH® prosthesis system and market share gains in core markets. The company achieved double-digit growth in the United States and EMEA regions. Medartis also introduced new products, such as the Titan Nail and a new Proximal Humerus system, to strengthen its portfolio.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
